RxDoctor Payments Data

Christopher Swanson

Internal Medicine · Riverside, CANPI 1023016847

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $317,800 of the $319,269 with a category attached, or 99.5%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 99.9% of it on its own, with 8 other manufacturers making up the rest. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$319,269in general payments, 2019–2025

Across 163 payments — averaging $1958.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$319K
  • Pfizer$43
  • Lilly USA, LLC$30
  • AstraZeneca$27
  • Esperion Therapeutics, Inc.$24
  • Alnylam Pharmaceuticals Inc.$22
  • plus $45 from 3 others

What the payments were for

  • Consulting fees$317,800100%
  • Travel & lodging$1,2780%
  • Food & beverage$1910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$319,269 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in Riverside

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →